Ask AI
ProCE Banner Activity

HER2CLIMB-02: Phase III Trial of Trastuzumab Emtansine ± Tucatinib in Previously Treated HER2-Positive MBC

Conference Coverage
Slideset

In the primary analysis of the phase III HER2CLIMB-02 trial, combination T-DM1 plus tucatinib showed improved median PFS compared with T-DM1 plus placebo in patients with previously treated HER2-positive MBC, including patients with brain metastases.

Released: December 08, 2023

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme, LLC

Seagen Inc.